Tissue-based Gene Expression Diagnosis of Mild and Moderate T-cell-mediated Rejection to Guide Therapy in Kidney Transplants
- PMID: 39710875
- DOI: 10.1097/TP.0000000000005296
Tissue-based Gene Expression Diagnosis of Mild and Moderate T-cell-mediated Rejection to Guide Therapy in Kidney Transplants
Abstract
Background: Mild histologic lesions of tubulo-interstitial inflammation could represent a "response-to-wounding" rather than allorecognition. Tissue gene expression may complement histopathology for T-cell-mediated rejection (TCMR) diagnostics.
Methods: We report on the incorporation of tissue gene expression testing using a Molecular Microscope Diagnostic System into the management of kidney transplant biopsies with suspected TCMR. Patients (N = 209) were divided into 3 groups based upon diagnosis and TCMR therapy (with high-dose steroids and/or anti-thymocyte globulin): Group 1: Untreated histologic TCMR with molecular quiescence (H+M-); Group 2: Treated histologic and molecular TCMR (H+M+); and Group 3: Controls, with no histologic or molecular (H-M-) rejection.
Results: At biopsy, estimated glomerular filtration rate was worse ( P = 0.006) in H+M+ (N = 35; 33 ± 22 mL/min/1.73 m 2 ) and H+M- (N = 30; 40 ± 18 mL/min/1.73 m 2 ) groups; compared with H-M- (N = 144; 47 ± 24 mL/min/1.73 m 2 ) group. In H+M- biopsies, mean molecular acute kidney injury scores (0.33 versus 0.10; P = 0.03) were higher than in H-M-; while molecular TCMR was lower compared with H+M+ (0.04 versus 0.54; P < 0.001). At 12 m postbiopsy estimated glomerular filtration rate remained low ( P < 0.001) in H+M+ (38 ± 22 mL/min/1.73 m 2 ) but improved in untreated H+M- (44 ± 22 mL/min/1.73 m 2 ) and H-M- (50 ± 23 mL/min/1.73 m 2 ) groups. At a mean follow-up of 2.1 ± 1.2 y post-index biopsy, death-censored graft survival was lower in H+M+ (74%) than in H+M- (90%) and H-M- (92%; P = 0.001). H+M+ cases had numerically higher rejection on follow-up biopsy (20%) than H+M- (7%) ( P = 0.12) and de novo donor-specific antibody formation (H+M+ 24%; H+M- 10%; P = 0.13).
Conclusions: In this large single-center study, biopsies with untreated histological TCMR and molecular quiescence had comparable clinical outcomes to cases with no rejection, whereas those with histologic and tissue gene expression confirmed TCMR had inferior outcomes.
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Similar articles
-
Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.Cochrane Database Syst Rev. 2017 Jan 11;1(1):CD004759. doi: 10.1002/14651858.CD004759.pub2. Cochrane Database Syst Rev. 2017. PMID: 28073178 Free PMC article.
-
Belatacept for kidney transplant recipients.Cochrane Database Syst Rev. 2014 Nov 24;2014(11):CD010699. doi: 10.1002/14651858.CD010699.pub2. Cochrane Database Syst Rev. 2014. PMID: 25416857 Free PMC article.
-
Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients.Cochrane Database Syst Rev. 2017 Jul 20;7(7):CD004756. doi: 10.1002/14651858.CD004756.pub4. Cochrane Database Syst Rev. 2017. PMID: 28731207 Free PMC article.
-
Defining the Etiology of Renal Allograft Dysfunction Using Banff 2019 Classification: Correlation with Post-Transplant Duration and Creatinine Levels-A Comprehensive Analysis of 200 Renal Biopsies at a Tertiary Care Medical Center Hospital.Int J Surg Pathol. 2025 May;33(3):615-622. doi: 10.1177/10668969241283737. Epub 2024 Oct 3. Int J Surg Pathol. 2025. PMID: 39360394
-
Protocol Biopsies in Delayed Graft Function Kidney Transplants From Brain-Dead Donors.Clin Transplant. 2025 Jul;39(7):e70228. doi: 10.1111/ctr.70228. Clin Transplant. 2025. PMID: 40663341 Free PMC article.
Cited by
-
Advancing therapeutic strategies for graft-versus-host disease by targeting gut microbiome dynamics in allogeneic hematopoietic stem cell transplantation: current evidence and future directions.Mol Med. 2025 Jan 3;31(1):2. doi: 10.1186/s10020-024-01060-x. Mol Med. 2025. PMID: 39754054 Free PMC article. Review.
References
-
- de Freitas DG, Sellares J, Mengel M, et al. The nature of biopsies with “borderline rejection” and prospects for eliminating this category. Am J Transplant. 2012;12:191–201.
-
- Wiebe C, Rush DN, Gibson IW, et al. Evidence for the alloimmune basis and prognostic significance of borderline T cell-mediated rejection. Am J Transplant. 2020;20:2499–2508.
-
- Loupy A, Haas M, Roufosse C, et al. The Banff 2019 Kidney Meeting Report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant. 2020;20:2318–2331.
-
- Nakagawa K, Tsuchimoto A, Ueki K, et al.; Japan Academic Consortium of Kidney Transplantation Investigators. Significance of revised criteria for chronic active T cell-mediated rejection in the 2017 Banff classification: Surveillance by 1-year protocol biopsies for kidney transplantation. Am J Transplant. 2021;21:174–185.
-
- Roufosse C, Simmonds N, Clahsen-van Groningen M, et al. A 2018 reference guide to the Banff classification of renal allograft pathology. Transplantation. 2018;102:1795–1814.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical